ReviewAlzheimer's research & therapy2022

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.

Sheila Seleri Assunção et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.